The dose-escalating, safety and tolerability study of the drug will be conducted at multiple sites in Australia and undertaken under both US and Australian regulatory authorizations.
Xenome has based its Xen2174 development strategies upon new knowledge of pain mechanisms, physicians’ patterns of clinical practice, healthcare systems and patient attitudes. An advantage of Xen2174’s mechanism of action is its ability to interact with a major natural pain-relieving pathway of the human body.
“The positive phase I safety results warrant further investigation of the potential safety and efficacy of Xen2174 in cancer pain patients, and also in the broader severe intractable pain market including neuropathic pain patients,” said Ian McRitchie, director of clinical development at Xenome.
According to the company, only an estimated 25% of people with severe painful conditions are treated effectively with currently available therapeutics.